Move to topTop
June 06, 2016

Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.

HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. The treatment involves producing skeletal myoblast sheets by culturing skeletal myoblasts contained in muscle tissue that has been taken from the patient's own thigh, and then transplanting the sheets onto the surface of the patient's heart.

HeartSheet is a product comprised of two kits: Kit A for collecting the patient's cells, and Kit B with cultured skeletal myoblasts and tools for producing sheets from cells. Kit A has already been sold to one medical institution, leading to the first case of patient cell collection covered by health insurance. Terumo estimates that the product will be used 20 to 30 cases per year for treatment.

To be a new alternative for therapies and a driver for the development of regenerative medicine

HeartSheet is expected to become a new alternative for the treatment of severe heart failure caused by chronic ischemic heart disease, for which conventional treatments, such as drug therapy and coronary artery bypass surgery,* lack efficacy.

  • *

    A surgical procedure for transplanting blood vessels from the legs or other body area to a blocked coronary artery to create an alternative path for blood to flow

In addition, HeartSheet was the first product to be designated as a conditional approval, a system put in place for the purpose of facilitating practical applications of regenerative medicine by the Ministry of Health, Labour and Welfare of Japan. The system is attracting attention among corporations and researchers involved in cellular and tissue-based products, and the utilization of the system is expected to promote advancements in regenerative medicine going forward.


The process of treatment using HeartSheet

Additional information

Terumo has been promoting joint research with Osaka University, where clinical research on skeletal myoblast sheets is being carried out by Professor Yoshiki Sawa as part of a project sponsored by the New Energy and Industrial Technology Development Organization (NEDO). Terumo has also participated in a research project on regenerative medicine using cell sheets. It is led by Professor Teruo Okano of Tokyo Women's Medical University, which is part of a special consortia involved in developing advanced medical care in Japan.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.